Compare · MDLN vs SOLV
MDLN vs SOLV
Side-by-side comparison of Medline Inc. (MDLN) and Solventum Corporation (SOLV): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SOLV operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $47.24B, about 3.2x SOLV ($14.85B).
- Over the past year, MDLN is down 11.8% and SOLV is up 20.2% - SOLV leads by 31.9 points.
- MDLN has been more active in the news (7 items in the past 4 weeks vs 1 for SOLV).
- MDLN has more recent analyst coverage (25 ratings vs 21 for SOLV).
PerformanceMDLN-11.77%SOLV+7.29%
2025-12-17+0.00%2026-10-16
- Company
- Medline Inc.
- Solventum Corporation
- Price
- $35.95-1.74%
- $85.80-2.32%
- Market cap
- $47.24B
- $14.85B
- 1M return
- +11.97%
- -1.96%
- 1Y return
- -11.77%
- +20.17%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- 2024
- News (4w)
- 7
- 1
- Recent ratings
- 25
- 21
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest SOLV
- Solventum to Report Third Quarter Fiscal 2026 Earnings on November 5, 2026
- Chief Executive Officer Hanson Bryan C converted options into 67,261 shares and covered exercise/tax liability with 26,468 shares, increasing direct ownership by 28% to 185,515 units (SEC Form 4)
- Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
- SEC Form 4 filed by SVP, Controller & CAO Zieselman Neil Craig
- SEC Form 3 filed by new insider Zieselman Neil Craig
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- SEC Form 10-Q filed by Solventum Corporation
- Solventum Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Solventum Reports Second Quarter 2026 Financial Results
- Solventum Corporation filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits